Shots:

• The company has initiated patient enrolment in P-III ULTRA-V trial evaluating Ukoniq + ublituximab + venetoclax- vs Ukoniq + ublituximab (U2) in patients with both frontline and r/r CLL. The 1EPs of the trial is PFS
• The company reports the completion of patient enrolment in the P-II ULTRA-V trial evaluating the triple combination of U2 + venetoclax in 165 patients with front line CLL- r/r CLL who were refractory to prior BTK therapy. The 1EPs of the trial is ORR and CRR
• The company launch a P-III study based on the P-I clinical results. Additionally- the initial results from the P-II ULTRA-V trial are expected in 2022

  Ref: TG Therapeutics | Image: Seeking Alpha